Eton Pharmaceuticals Won US Patent for Proprietary Hydrocortisone Oral Liquid Formulation
Portfolio Pulse from Benzinga Newsdesk
Eton Pharmaceuticals (NASDAQ:ETON) has been granted a U.S. patent for its proprietary oral liquid hydrocortisone formulation, ET-400, by the USPTO. The patent, expiring in 2043, is expected to be listed in the FDA's Orange Book upon approval. Eton has additional patent applications under review for the product.
February 21, 2024 | 11:55 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eton Pharmaceuticals has been granted a U.S. patent for ET-400, its oral liquid hydrocortisone formulation, with an expiration in 2043. This patent is a significant step towards FDA approval and commercialization.
The granting of a U.S. patent for Eton Pharmaceuticals' ET-400 product candidate is a critical development for the company. It not only secures the company's intellectual property rights for this formulation until 2043 but also enhances its prospects for FDA approval and commercial success. Given the patent's expected listing in the FDA's Orange Book, this development is likely to be viewed positively by investors, potentially leading to a short-term increase in ETON's stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100